Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LATS1 | O95835 | 1/20 | 0.41 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3972075 | 0.91 | ADORA3 (0.52) | POLBADORA3MEN1KMT2ALATS1 | |
| SCHEMBL3975242 | 0.87 | RAD52 (0.45) | POLBKMT2ALATS1LATS2SYK | |
| SCHEMBL3974313 | 0.82 | PDE5A (0.60) | POLBADORA3CYP1A2CYP2D6MEN1 | |
| SCHEMBL3975863 | 0.81 | KDM1A (0.49) | POLBKMT2ALATS1LATS2SYK | |
| SCHEMBL3971156 | 0.78 | POLB (0.60) | POLBFLT3MAPK1 | |
| SCHEMBL3978935 | 0.78 | LATS1 (0.52) | POLBADORA3LATS1LATS2MAPK1 | |
| SCHEMBL3974463 | 0.76 | HTR3A (0.48) | POLBADORA3MEN1KMT2ATSHR | |
| SCHEMBL3972857 | 0.76 | NPC1 (0.50) | ADORA3CYP1A2MEN1KMT2ANPC1 | |
| SCHEMBL3977126 | 0.74 | GBA1 (0.49) | POLBADORA3MEN1KMT2ATSHR | |
| SCHEMBL3972107 | 0.72 | LATS1 (0.50) | LATS1LATS2MAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547702-B2 | 4-amino-quinazolines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | SERPINA3, APOL1, MGAT3 | POLB 4723/4885ADORA3 448/4885CYP1A2 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.